Determination of the presence of interleukin-6 in bile after orthotopic liver transplantation - Its role in the diagnosis of acute rejection

被引:24
作者
Umeshita, K
Monden, M
Tono, T
Hasuike, Y
Kanai, T
Gotoh, M
Mori, T
Shaked, A
Busuttil, RW
机构
[1] OSAKA UNIV,SCH MED,DEPT SURG 2,SUITA,OSAKA 565,JAPAN
[2] UNIV CALIF LOS ANGELES,SCH MED,DEPT SURG,LOS ANGELES,CA 90024
关键词
D O I
10.1097/00000658-199602000-00014
中图分类号
R61 [外科手术学];
学科分类号
摘要
Objective The authors evaluated the significance of interleukin-6 (IL-6) in bile in the diagnosis of acute rejection after liver transplantation. Summary Background Data Interleukin-6 in blood has not been shown to be useful as a marker of acute rejection in clinical liver transplantation. In a rat liver transplantation model, the authors have round that bile IL-6 levels correlated well with the severity of rejection as determined histologically, whereas kinetics of serum IL-6 differed among rats without any definite feature related to graft rejection. Methods Fifty-one patients who underwent orthotopic liver transplantation between May 1990 and February 1991 at the University of California, Los Angeles, were included in the study. After liver transplantation, bile and blood were collected daily, and IL-6 levels were measured by the enzyme-linked immunosorbent assay. Results Bile IL-6 increased to 1228 +/- 317 pg/mL on the day of transplantation and decreased to 50 pg/ mL or less within 48 hours. Patients who had uneventful postoperative courses had low levels of bile IL-6 throughout their hospitalization. In patients with acute rejection, bile IL-6 significantly increased (1090 +/- 990 pg/mL; p < 0.05), but decreased in response to antirejection therapy. In patients who had liver dysfunction due to ischemic change or sepsis, bile IL-6 did not increase. Patients with cholangitis had significantly increased levels of bile IL-6 (146 +/- 47; p < 0.05). Interleukin-6 in blood increased with many kinds of complications other than rejection and seemed to be less specific than that in bile. Conclusions Measurement of IL-6 in bile may be a useful, noninvasive tool for diagnosing acute rejection.
引用
收藏
页码:204 / 211
页数:8
相关论文
共 38 条
[1]   PRODUCTION OF HYBRIDOMA GROWTH-FACTOR BY HUMAN-MONOCYTES [J].
AARDEN, LA ;
DEGROOT, ER ;
SCHAAP, OL ;
LANSDORP, PM .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1987, 17 (10) :1411-1416
[2]   THE 1ST 100 LIVER-TRANSPLANTS AT UCLA [J].
BUSUTTIL, RW ;
COLONNA, JO ;
HIATT, JR ;
BREMS, JJ ;
ELKHOURY, G ;
GOLDSTEIN, LI ;
QUINONESBALDRICH, WJ ;
ABDULRASOOL, IH ;
RAMMING, KP .
ANNALS OF SURGERY, 1987, 206 (04) :387-402
[3]  
CALNE R, 1987, LIVER TRANSPLANTATIO
[4]   PRODUCTION OF B-CELL STIMULATORY FACTOR-II AND INTERFERON-GAMMA IN THE CENTRAL NERVOUS-SYSTEM DURING VIRAL MENINGITIS AND ENCEPHALITIS - EVALUATION IN A MURINE MODEL INFECTION AND IN PATIENTS [J].
FREI, K ;
LEIST, TP ;
MEAGER, A ;
GALLO, P ;
LEPPERT, D ;
ZINKERNAGEL, RM ;
FONTANA, A .
JOURNAL OF EXPERIMENTAL MEDICINE, 1988, 168 (01) :449-453
[5]   B-CELL-STIMULATORY FACTOR-II (BETA-2 INTERFERON) FUNCTIONS AS A 2ND SIGNAL FOR INTERLEUKIN-2 PRODUCTION BY MATURE MURINE T-CELLS [J].
GARMAN, RD ;
JACOBS, KA ;
CLARK, SC ;
RAULET, DH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (21) :7629-7633
[6]  
GARMAN RD, 1987, J IMMUNOL, V138, P1121
[7]   INTERFERON BETA-2/B-CELL STIMULATORY FACTOR TYPE-2 SHARES IDENTITY WITH MONOCYTE-DERIVED HEPATOCYTE-STIMULATING FACTOR AND REGULATES THE MAJOR ACUTE PHASE PROTEIN RESPONSE IN LIVER-CELLS [J].
GAULDIE, J ;
RICHARDS, C ;
HARNISH, D ;
LANSDORP, P ;
BAUMANN, H .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (20) :7251-7255
[8]   COMPLEMENTARY-DNA FOR A NOVEL HUMAN INTERLEUKIN (BSF-2) THAT INDUCES LYMPHOCYTES-B TO PRODUCE IMMUNOGLOBULIN [J].
HIRANO, T ;
YASUKAWA, K ;
HARADA, H ;
TAGA, T ;
WATANABE, Y ;
MATSUDA, T ;
KASHIWAMURA, S ;
NAKAJIMA, K ;
KOYAMA, K ;
IWAMATSU, A ;
TSUNASAWA, S ;
SAKIYAMA, F ;
MATSUI, H ;
TAKAHARA, Y ;
TANIGUCHI, T ;
KISHIMOTO, T .
NATURE, 1986, 324 (6092) :73-76
[9]  
HIRANO T, 1990, HDB EXPT PHARM PEPTI, P633
[10]  
HORII Y, 1988, J IMMUNOL, V141, P1529